Professor Sara Ghorashian is a Consultant Paediatric Haematologist at Great Ormond Street Hospital for Children (GOSH) in London, specialising in the diagnosis and treatment of childhood blood cancers and advanced cellular therapies. GOSH identifies her as one of its clinicians working in Blood, Cells and Cancer, and in September 2026 announced her promotion to professor by University College London.

Professor Ghorashian has developed particular expertise in CAR-T cell therapy, an advanced form of personalised cancer treatment that modifies a patient's immune cells so they can recognise and attack cancer cells. Her work has contributed to the development of innovative treatment approaches for children whose blood cancers have relapsed or become resistant to conventional therapies.

Her clinical and research interests include childhood leukaemia, cellular therapy, immunotherapy, and early-phase clinical research. GOSH has documented her leadership in clinical research involving children with aggressive forms of blood cancer. In 2024, she was identified as the lead investigator of a clinical trial investigating CAR-T cell therapy for young people with relapsed or treatment-resistant T-cell acute lymphoblastic leukaemia.

Professor Ghorashian has also been involved in the development and delivery of CAR-T treatments at GOSH for many years. The hospital has highlighted her role in both laboratory development and clinical application of CAR-T therapy. GOSH reported that its CAR-T programme had treated children through clinical studies before licensed CAR-T treatment became available through the NHS.

Her research approach combines laboratory science with clinical care. This translational model is particularly important in paediatric oncology because children with relapsed or refractory cancers may have limited treatment options. By studying how engineered immune cells behave after treatment, research teams can work toward improving durability, safety, and effectiveness.

Professor Ghorashian's work also reflects GOSH's close relationship with University College London and the UCL Great Ormond Street Institute of Child Health. Her professorial appointment in 2026 recognised her contribution to research, innovation, and child health. GOSH specifically highlighted her role in developing new treatment options for children with blood cancers.

For families seeking specialist paediatric cancer care, her clinical area covers complex blood malignancies requiring specialist haematology, oncology, cellular therapy, and multidisciplinary support. Treatment planning for childhood cancer can involve chemotherapy, immunotherapy, transplantation, cellular therapies, and participation in clinical trials depending on the diagnosis and individual circumstances.

Her research into CAR-T therapy is particularly relevant to children with difficult-to-treat or relapsed disease. GOSH has reported that her research programme is exploring new approaches designed to make advanced therapies available to children alongside adult research rather than delaying paediatric development.

Professor Sara Ghorashian's combination of paediatric haematology, cellular therapy research, and clinical trial involvement makes her an important clinician within GOSH's Blood, Cells and Cancer services. Her work illustrates the hospital's focus on combining specialist children's healthcare with research into next-generation treatments.

For international patients, families should confirm current clinic availability, referral requirements, eligibility for specialist treatments, and clinical-trial participation directly with Great Ormond Street Hospital before making treatment arrangements.